Elixir Medical touted clinical and imaging results from a study of its DynamX drug-eluting stent, which is designed to restore normal pulsatility and adaptive remodeling in blood vessels after treating a coronary lesion. DynamX, introduced in 2017 at the annual Transcatheter Cardiovascular Therapeutics meeting, is a cobalt-chromium stent with a biodegradable polymer coating that releases novolimus. […]
Neovasc surges on two-year Reducer results
Two-year data from a trial of the Reducer anti-angina device made by Neovasc (NSDQ:NVCN), published this week in the International Journal of Cardiology, bore out earlier safety and efficacy results but showed no effect on the progression of coronary artery disease. The study examined angina symptoms, quality of life and adverse events at two years, […]
Neovasc closes $12m offering
Neovasc (NSDQ:NVCN) said yesterday that it closed the $11.5 million offering it announced earlier this week. Proceeds from the offering will be used to support continued development and commercialization of its Reducer device, and development of its Tiara device, the Vancouver-based company said. In the offering, Neovasc said that it sold a 15% original issue discount convertible […]
Neovasc raises $12m
Neovasc (NSDQ:NVCN) said today that it raised approximately $11.5 million through the combined sale of shares of its stock and convertible debt. The Vancouver-based company said that it inked an agreement to sell Strul Medical Group a 15% original issue discount convertible note with a face value of $11.5 million, expecting to see gross proceeds of […]
Neovasc plunges on Q1 misses
Neovasc (NSDQ:NVCN) shares are taking a beating this morning after the company released first-quarter results yesterday that badly missed the consensus forecast. Vancouver-based Neovasc pared its losses by -85.7% to -$7.9 million, or -21¢ per share, on sales growth of 72.3% to $585,800 compared with Q1 2018. Analysts on Wall Street were looking for losses […]
Neovasc settles final spat with Edwards unit CardiAQ Valve
Neovasc (NSDQ:NVCN) said late yesterday that it resolved the last remaining patent litigation between it and Edwards Lifesciences (NYSE:EW) subsidiary CardiAQ Valve Technologies by adding members of CardiAQ as co-inventors of the patents in dispute. Vancouver-based Neovasc said that it added CardiAQ’s Jeremy Brent Ratz and Arshad Quadri as co-inventors of three patents, each of which was related […]
Neovasc gains on Reducer study
Shares of Neovasc (NSDQ:NVCN) are up today after the medical device company released study results showing that its Reducer device for treating angina doesn’t worsen heart function and may in fact help. The Vancouver-based company said the 24-patient study of patients treated with Reducer, which is designed to narrow the coronary sinus, showed no significant […]
Neovasc shares tumble on 2018 earnings release
Shares in Neovasc (NSDQ:NVCN) have fallen nearly 10% today after the medical device maker posted full year 2018 earnings that showed losses growing to more than triple what it reported in 2017. The Vancouver-based company posted losses of $109.1 million, or $7.63 per share, on sales of $1.7 million, seeing losses grow 338.7% while sales shrunk […]
Neovasc claims win in German TMVR patent case against Edwards unit CardiAQ Valve
Neovasc (NSDQ:NVCN) today claimed a win in its patent infringement war with Edwards Lifesciences (NYSE:EW) subsidiary CardiAQ Valve Technologies, saying a German appeals court dismissed a case there. In June 2017 the District Court in Munich ruled that CardiAQ Valve contributed to the creation of Neovasc’s Tiara transcatheter mitral valve replacement, awarding”co-entitlement” rights to the patent in […]
Neovasc retains EC Marking after EU surveillance audit
Updated to correct from CE Marking to EC Marking. Neovasc (NSDQ:NVCN) said yesterday that it successfully completed its 2019 mandatory surveillance audit with its notified body in the European Union. The Vancouver-based company said that as a result of the successful audit, and its maintenance of the ISO 13485: 2016 certification of its quality management system, […]
Neovasc prices $5m offering
Neovasc (NSDQ:NVCN) today priced an upcoming offering looking to raise $5 million to support its Tiara and Reducer devices. In the round, the Vancouver-based company will look to float approximately 11.1 million shares of its common stock at a price of 45¢ per share. The offering is expected to close on March 15, the company said. […]
- 1
- 2
- 3
- …
- 7
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube